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Introduction: Association between high serum homocysteine (S-Hcy) levels and low bone 
mineral density (BMD) and increased fracture risk in postmenopausal women has been 
documented. Data concerning S-Hcy and bone health in children are scarce.
Objective: Our aim was to evaluate S-Hcy in children and adolescents with impaired bone 
health and look for correlations with clinical and laboratory data.
Patients and methods: We assessed S-Hcy levels in 37 children and adolescents (22 boys and 
15 girls; mean age 13.9 ± 3.5 years) with prevalent low-energy trauma fractures (mean 3.3 
± 2.3 per patient) and/or low spinal L1-L4 BMD (below -2SD Z-score; DXA Lunar GE). We 
also evaluated S-ALP, serum CrossLaps, osteocalcin (S-OC), body height, weight, body mass 
index (BMI) and serum levels of folate and vitamin B12. At the time of assessment, the chil-
dren were not taking any drugs known to influence bone metabolism. The age-dependent 
parameters were expressed as Z-scores ± SD. 
Results: S-Hcy Z-score was significantly higher (1.3 ± 1.5; P < 0.0001) and L1-L4 BMD Z-score 
was significantly lower (-1.7 ± 1.3; P < 0.0001), respectively, in comparison with reference 
values. S-ALP did not differ from reference values (P = 0.88), while S-CrossLaps and S-osteo-
calcin were higher (1.2 ± 1.8 and 0.4 ± 0.5; P = 0.0001 and P = 0.001, respectively). S-Hcy was 
inversely correlated to L1-L4 BMD (r = -0.33; P = 0.05) and S-ALP (r = -0.36; P = 0.04) and not 
related to number of prevalent fractures (r = 0.01), S-osteocalcin (r = -0.22) or S-CrossLaps 
(r = 0.003).
Conclusion: These results suggest increased bone turnover and negative influence of elevat-
ed S-Hcy on bone formation and BMD in children and adolescents with recurrent fractures. 
© 2013 Elsevier Editora Ltda. All rights reserved.
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Níveis séricos de homocisteína em crianças e adolescentes com 
comprometimento da saúde óssea
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r e s u m o
Introdução: Foi documentada uma associação entre níveis séricos elevados de homocisteína 
(S-Hci) e baixa densidade mineral óssea (DMO) e aumento do risco de fratura em mulhe-
res na pós-menopausa. São escassos os dados concernentes à S-Hci e à saúde óssea em 
crianças. 
Objetivo: Avaliar S-Hci em crianças e adolescentes com comprometimento da saúde óssea 
e procurar por relações com dados clínicos e laboratoriais.
Pacientes e métodos: Avaliamos os níveis de S-Hci em 37 crianças e adolescentes (22 meni-
nos e 15 meninas; média de idade, 13,9 ± 3,5 anos) com fraturas prevalentes por trauma de 
baixa energia (média 3,3 ± 2,3 por paciente) e/ou baixa DMO espinhal/L1-L4 (escore Z abaixo 
de -2 DP; DXA Lunar GE). Também avaliamos S-ALP, CrossLaps sérico (S-Hci-CrossLaps), os-
teocalcina (S-OC), altura, peso corporal, índice de massa corporal (IMC) e níveis séricos de 
folato e vitamina B12. Por ocasião da avaliação, as crianças não estavam tomando qualquer 
medicação que sabidamente influenciasse o metabolismo ósseo. Os parâmetros dependen-
tes de idade foram expressos como escores Z ± DP. 
Resultados: O escore Z para S-Hci foi significativamente mais alto (1,3 ± 1,5; P < 0,0001) e o 
escore Z de para DMO/L1-L4 foi significativamente mais baixo (-1,7 ± 1,3; P < 0,0001), res-
pectivamente, em comparação com os valores de referência. S-ALP não diferiu dos valores 
de referência (P = 0,88), enquanto S-CrossLaps e S-osteocalcina foram mais elevados (1,2 ± 
1,8 e 0,4 ± 0,5; P = 0,0001 e P = 0,001, respectivamente). S-Hci estava inversamente correla-
cionada com DMO/L1-L4 (r = -0,33; P = 0,05) e S-ALP (r = -0,36; P = 0,04) não tendo relação 
com o número de fraturas prevalentes (r = 0,01), S-osteocalcina (r = -0,22) ou S-CrossLaps 
(r = 0,003).
Conclusão: Esses resultados sugerem aumento na remodelação óssea e uma influência ne-
gativa da S-Hci elevada na formação óssea e na DMO em crianças e adolescentes com 
fraturas recorrentes.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Homocysteine is an amino acid which is biosynthesized 
from methionine by the removal of its terminal C methyl 
group. Furthermore, homocysteine can be recycled into 
methionine or converted into cysteine. The homocysteine 
metabolism is dependent on vitamin B6, B9, B12 status and 
also on serum folate concentration.1,2 High serum homocys-
teine level (S-Hcy) is associated with alterations in vascular 
morphology, loss of endothelial anti-thrombotic function, 
and induction of a procoagulant environment, and has been 
linked to cardiovascular and neurodegenerative disease, dia-
betes, thrombosis, and Raynaud’s phenomenon.2-4
Associations between high S-Hcy levels and low bone min-
eral density (BMD) and increased fracture risk in postmeno-
pausal women have been repeatedly documented.5-13 To date, 
there are scarce data concerning S-Hcy and bone health in 
children and adolescents. In our recent pilot study involving 
19 children (12 boys and 7 girls; mean age 14.9 ± 3.3 years) 
with recurrent fractures and low BMD, we observed elevated 
S-Hcy (Table 1) with high inverse and significant correlations 
between S-Hcy and BMD (r = -0.66; P = 0.01) and S-Hcy and se-
rum alkaline phosphatase activity (S-ALP) (r = -0.56; P = 0.03), 
respectively.14 S-Hcy was not related to number of prevalent 
fractures (r = 0.11) or S-CrossLaps (r = -0.14).14
Therefore, we further analysed S-Hcy levels together with 
indices of bone turnover and several clinical and biochemi-
cal parameters in a group of 37 children and adolescents 
with low BMD and/or prevalent low-energy trauma fractures.
Patients and methods
Patients
We evaluated the charts of children and adolescents who at-
tended our Pediatric Bone Clinic at The Department of Pe-
Table 1 – Patient data from previous pilot study (n = 19),14 
expressed as Z-scores ± SD.
Parameter Mean SD Pa
S-homocysteine 1.4 1.8 0.001
L1-L4 BMD -2.1 1.3 0.0001
S-ALP  0.03 1.0 0.91
S-CrossLaps 1.5 1.9 0.001
Height -0.06 1.0 0.27
BMD, bone mineral density; S-ALP, serum alkaline phosphatase 
activity.
a Compared to reference data.
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diatrics in Pardubice in the years 2006-2012. The inclusion 
criteria were: (i) age between five and 20 years; (ii) at least 
two prevalent low-energy trauma fractures in personal his-
tory; or (iii) low spinal L1-L4 BMD (below -2 SD Z-score); or 
(iv) a combination of both. 
Four children with less than two prevalent fractures and 
low BMD were included. In these four children, the BMD mea-
surement was performed due to the following reasons: in one 
boy with no prevalent fracture, the BMD measurement was 
performed due to presence of bone fragility risk factors (life-
long immobilisation after intracranial hemorrhage); in two 
girls without fractures, BMD was measured due to estimation 
of low bone density on the X-ray of the extremities performed 
by a surgeon after soft tissue injuries; and in one girl due to 
presence of one low-energy trauma femoral fracture. 
The subjects were not eligible for evaluation if they were 
taking any drugs known to influence bone metabolism (al-
facalcidol, calcitriol, dihydrotachysterol, bisphosphonates, 
glucocorticosteroids, anabolic steroids, antiepileptics, thia-
zides, furosemide, thyroid hormones, growth hormone, hep-
arin, warfarin) at the time of the assessment or at any time 
before. The subjects with diabetes mellitus, celiac disease, 
inflammatory bowel disease, autoimmune disorders, Cush-
ing syndrome, chronic renal failure, hypercalciuria, urolithi-
asis, hyper- and hypothyroidism, hyper- and hypoparathyri-
odism were also excluded. 
All subjects were on a standard central European diet, con-
sisting mostly of meat and carbohydrates. None was on a diet 
poor in vitamin B, nor was receiving doses of vitamin B exce-
eding the recommended daily allowances. One obese boy was 
treated for hypertension with enalapril. Others were normo-
tensive. Therefore, we included 37 children and adolescents 
(22 boys and 15 girls; age range 7-20 years; mean age 13.9 ± 
3.5 years).
Procedures
We evaluated the following data in all 37 patients: S-HCy, 
markers of bone formation: total S-ALP and serum osteocal-
cin (S-OC), marker of bone resorption serum Crosslaps, serum 
calcium (S-Ca), serum phosphate (S-P), serum levels of folate 
and vitamin B12, body height, weight, body mass index (BMI), 
and L1-L4 spinal BMD. S-cholesterol was also evaluated. The 
biochemical parameters were assessed from a single morning 
blood draw in fasting patients.
Materials and methods
Body height was measured on the day of the relevant blood 
draw to the nearest ± 0.5 cm on a calibrated stadiometer.
Body weight was measured on the same day on a calibrated 
scale to ± 0.5 kg. 
The BMI was calculated using the equation BMI = weight 
(kg)/height2 (m).
BMD was measured at spine (L1-L4) with dual energy X-ray 
absorptiometry (DXA) Lunar GE at the day of the blood draw. 
Measurement precision, expressed as coefficient of variation, 
was 1.0%.
S-homocysteine level was evaluated by chemilumines-
cence (Immulite 2500 immunoassay system, Siemens Health-
care Diagnostics, Germany) and expressed in μmol/L. The 
interassay variation was 2.06% in samples with S-Hcy concen-
tration 7.43 μmol/L; 1.99% with S-HCy 10.31 μmol/L, and 1.72% 
with S-Hcy 22.25 μmol/L, respectively. S-Ca and S-P were as-
sessed by colorimetric assay and expressed in mmol/L. S-ALP 
was measured by colorimetric assay and expressed in μkat/L.
Serum CrossLaps and S-OC were assessed by means of 
electrochemiluminescence immunoassay – ECLIA on Elecsys-
Cobas analyzers and expressed in ng/L and ng/mL, respec-
tively.
Serum folic acid and serum vitamin B12 (S-B12) were as-
sessed by chemiluminiscence on Access analyzer (Beckman 
Coulter) and expressed in μg/L and ng/L, respectively.
Statistics
To eliminate the influence of age, the obtained results of body 
height, weight, BMI, S-HCy, S-ALP, S-CrossLaps, and S-OC were 
calculated as standard deviation scores (SDS) or Z-scores by 
the equation SDS = (actual individual value – mean value for 
age and sex)/standard deviation for age and sex. The BMD refe-
rence data (concerning European paediatric population) were 
supplied by the manufacturer within the DXA software pac-
kage. Previously published results served as reference data: 
Czech anthropometric parameters from a 2001 survey,15 pre-
viously obtained HCy values of healthy Czech paediatric po-
pulation,16 S-ALP values of Czech children,17 and S-CTx levels 
of healthy British population.18 The normal S-OC range was 
determined in 77 children aged 7-19 years without evidence of 
bone, hepatic, renal, gastrointestinal or endocrine disorders. 
For statistical analysis, Sigmaplot 2.0 and Systat programme 
were used. The statistical analysis was performed by unpaired 
t-test. The linear regression analysis was performed to com-
pare the relationship among respective parameters. For all re-
sults, P < 0.05 was required for statistical significance.
Results
The mean number of prevalent low-energy trauma fractures 
was 3.3 ± 2.3 (SD) per patient. The mean S-homocysteine level 
was 10.7 μmol/L ± 2.9 SD; range 6.7-20 μmol/L. There was a sig-
nificant positive correlation with age (r = 0.47, P < 0.01) (Fig. 1).
Seven patients (19%) had S-homocysteine level above +2 
SD, 30 patients (81%) had S-homocysteine levels in the range 
of ± 2 SD.
When converted to Z-scores and compared with reference 
values, the S-Hcy Z-score was significantly higher and L1-L4 
BMD Z-score was significantly lower, respectively, in compari-
son with reference values. S-ALP Z-score did not differ from 
reference values, while S-CrossLaps were higher, same as 
S-OC (Table 2).
The mean levels of S-folate and B12 were 7.5 μg/L ± 4.2 
SD and 413 ng/L ± 143 SD, which fall within normal reference 
ranges of 2.3-17 μg/L and 180-914 ng/L, respectively.
S-Ca and S-P levels were within normal reference range 
(mean ± SD: 2.33 ± 0.10 mmol/L; range 2.13-2.54; and 1.45 ± 
0.23 mmol/L; range 0.78-1.99, respectively). Mean S-cholesterol 
level was 4.21 ± 0.96 mmol/L (range 3.06-5.59 mmol/L), therefo-
re within the normal reference range of 2.7-5.6 mmol/L.
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Mean body height, body weight, and BMI Z-score did not 
differ from reference values (Table 2), however in fi ve sub-
jects the BMI Z-score exceeded + 2 SD. The body height, 
weight and BMI Z-scores positively correlated with L1-L4 
BMD Z-score (r = 0.44, 0.53 and 0.50, respectively; P = 0.02).
S-Hcy was inversely correlated to L1-L4 BMD (Fig. 2) and S-
-ALP (Fig. 3), respectively, and not related to number of preva-
lent fractures (r = 0.11), S-osteocalcin (r = -0.22) or S-CrossLaps 
(r = 0.003).
There was signifi cant inverse correlation between S-Hcy 
and vitamin B12 (r = -0.36, P = 0.05) and no correlation be-
tween S-Hcy and serum level of folic acid (r = 0.05).
Furthermore, we found positive correlations between S-os-
teocalcin and S-CTx (r = 0.36, P = 0.05), S-ALP and S-OC (r = 0.58, 
P = 0.01), and S-CTx and S-ALP (r = 0.39, P = 0.05), respectively.
Discussion
In our previous pilot study of 19 children with prevalent fra-
ctures and low BMD, the obtained results suggested negati-
ve infl uence of elevated S-Hcy on bone formation and BMD, 
while bone resorption was increased in this group of pediat-
ric patients.14 In an expanded group of 37 children with im-
paired bone status, we obtained very similar results. S-Hcy 
was elevated and inversely correlated with S-ALP and BMD. 
Furthermore, we found indices of increased bone turnover 
in our patients, as S-OC and S-Crosslaps were elevated in 
comparison to the reference data, and there were positi-
ve mutual correlations among the bone turnover markers. 
The low BMD in our patients was not infl uenced by stun-
ted growth, as the body height did not differ from reference 
value, however our results confi rm dependence of BMD on 
basic anthropometric parameters. As there is a proven as-
Table 2 – Patient data from currently presented study (n 
= 37) expressed as Z-scores ± SD.
Parameter Mean SD Pa
S-homocysteine 1.31 1.49 < 0.0001
L1-L4 BMD -1.74 1.32 < 0.0001
S-ALP 0.02 1.01 0.88
S-CrossLaps 1.21 1.79 0.0001
S-osteocalcin  0.38 0.53  0.001
Height -0.05 1.31 0.82
Weight 0.18 1.62 0.50  
BMI 0.48 1.88 0.12
BMD, bone mineral density; S-ALP, serum alkaline phosphatase 
activity; BMI, body mass index.
a Compared to reference data.
Fig. 2 – S-homocysteine (Z-score) vs. bone mineral density 
(Z-score). R = -0.33, P = 0.05.
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Fig. 3 – S-homocysteine (Z-score) vs. S-alkaline 
phosphatase activity (Z-score). R = -0.36, P = 0.04.
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Fig. 1 – S-homocysteine (μmol/L) vs. age (years). R = 0.47, 
P < 0.01.
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sociation between low bone density and fractures in chil-
dren,19,20 hyperhomocysteinemia might represent an impor-
tant risk factor for children´s bone health. Furthermore, in 
adults, an association between high S-Hcy and low BMD was 
reported by several authors,6,11 same as high S-HCy in os-
teoporotic postmenopausal women with no relationship to 
BMD values.7 In addition, further research revealed that high 
homocysteine levels are associated with an increased risk of 
hip fracture in elderly population.10
From the pathophysiological point of view, osteoporosis 
and higher fracture risk in patients with high S-Hcy are cur-
rently explained by accumulation of homocysteine in bone, 
resulting in a distinct reduction of cancellous bone and a 
drop in bone strength.9 Furthermore, homocysteine stimu-
lates osteoclast activity.21 A reduced methylation capacity of 
bone cells might contribute as well.22
As we did not find any relationship between the num-
ber of prevalent fractures and S-Hcy in our patient group, we 
may hypothesize that the study was not powered enough 
to detect significant relationship between these two pa-
rameters. Concerning the cardiovascular risk factors, the S-
cholesterol and BMI were not significantly elevated in our 
patients, and only one subject was hypertensive.
Anyway, our results further confirm the negative effect 
of elevated S-Hcy on bone health. even in pediatric popula-
tion. The developmental aspects of various disease states of 
the elderly (i.e. osteoporosis, high blood pressure, hypecho-
lesterolemia, obesity) are currently being given special at-
tention, as these disorders usually originate in childhood. It 
seems likely that the effect of homocysteine on bone quality 
is this case as well.
Conclusion 
Our results further suggest that elevated S-Hcy could be a 
risk factor of impaired bone health in children and adoles-
cents.
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